FREE TREATMENT REPORT
See ratings and reviews when you sign up for an account.
The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being
This study is currently Recruiting
December 2001 By National Taiwan University Hospital
First Recieved on September 9, 2005
Last Updated on December 19, 2005
Cervical cancer the most frequent neoplasm and the third mortality rate of malignancies of
the women in the world. It results in about 200,000 women dying of cervical cancer each year
worldwide. The available forms of treatment-surgery, radiation therapy, and chemotherapy are
all cytoreductive treatment modalities, so in addition to killing cancerous cells, healthy
cells are also destroyed in the process. Indeed, there is a need to decrease the incidence
of cervical cancer and develop better forms of its treatment.
Human papilloma viruses (HPV) have been consistently implicated in causing cervical cancer
especially those high-risk types (HPV 16,18,31,45) have been strongly associated with
cervical cancer. HPV 16 was found in more than 50% of cervical cancer tissues. So the host
immune response plays an important role in determining the regression of cervical
abnormality or persistence and progression to malignancy via targeting HPV.
The ideal cancer treatment should be able to eradicate systemic tumors at multiple sites in
the body while having the specificity to discriminate between neoplastic and nonneoplastic
cells. In this regard, antigen-specific cancer immunotherapy represent an attractive
approach for cancer treatment. It is now clear that major histocompatibility complex (MHC)
class I restricted CD8+ T cytotoxic cells are critical to the generation of antitumor
immunity. Cell-mediated responses are critical in anti-tumor immunity.
By cooperating with Dr. TC Wu in Johns Hopkins Medical Institutes, we have recently
developed some E7-specific cancer vaccines of different strategies such as DNA, or
replication-defective SINrep5 virus. We found that these E7-chimeric DNA vaccines are
capable of preventing and treating the growth of murine model tumors expressing E7. These
positive results from the preclinical murine models have encouraged us to focus on the
development of cancer vaccine and immunotherapy and apply these vaccines to human subjects.
However, it is very important to set up various E7-specific immunologic assays of human
being to evaluate the effect of cancer vaccine or immunotherapy in the future clinical
trials. So we would like to provide this proposal to address on the development of HPV 16
E7-specific immunologic assays in human being.
||Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional, Time Perspective: Prospective
Resources/Links provided by NLM:
|Study Start Date:
|Estimated Primary Completion Date:
|Ages Eligible for Study:||18 Years|
|Genders Eligible for Study:||Female|
|Accepts Healthy Volunteers:||Accepts Healthy Volunteers|
normal volunteer, patients with CIN lesions or cervical cancers whose HLA haplotype is not
- Investigator: Wen-Fang Cheng, MD, PhD - Principal Investigator - National Taiwan University Hospital
- National Taiwan University Hospital